Corporate Presentation which shall be discussed at the upcoming Investor Conferences/Meets is herewith enclosed.
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Acutaas Chemicals (formerly Ami Organics) shared its corporate presentation ahead of investor meetings. The specialty chemical manufacturer posted FY26 revenue of ₹13,394 Mn, up 33% from ₹10,069 Mn in FY25. Net profit surged 122% to ₹3,564 Mn with PAT margin expanding to 26.6% from 15.9% previously. EBITDA stood at ₹4,804 Mn (35.9% margin). The company operates across pharma intermediates (87.7% of revenue), commodity chemicals (11.2%), semiconductor chemicals (1.2%), and early-stage battery chemicals. Acutaas holds 50-90% global market share in key pharma intermediates and is India’s only manufacturer of photoresist chemicals with parts-per-billion purity. The company plans ₹1,000+ Cr capex through FY30, with ongoing investments in battery chemicals (~₹220 Cr), South Korea semiconductor JV (~₹200 Cr), and R&D (~₹25 Cr). Market cap is ₹20,948 Cr with 32.7% promoter holding.
Strong financial growth with margin expansion signals operational efficiency improvements. The multi-year capex roadmap (₹1,000+ Cr through 2030) indicates significant future investment in battery and semiconductor chemicals, positioning the company for diversification beyond its dominant pharma intermediates business.